AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04043923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen
Description: Oral capsule
Study NCT04043923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT00487409 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bipolar electrosurgical generator and instruments
Description: laparoscopic colectomy using the Ligasure device
Study NCT00487409 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Disposable stapling instruments
Description: laparoscopic colectomy using clips, cautery and stapler
Study NCT02072356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: Given Interartrial
Study NCT02072356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Alpha-fetoprotein assay
Study NCT04244084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMH-407
Description: Oral use.
Study NCT04244084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use.
Study NCT03240289 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Texting group
Description: Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
Study NCT00477399 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Long term follow up after intensive lifestyle intervention
Study NCT04414020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesteron
Description: intramusculer progesterone
Study NCT03224000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Barium Swallow (MBS)
Description: Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT03224000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Barium Swallow (MBS)
Description: Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT02072356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: TheraSphere is delivered into the liver tumor through a catheter placed into the hepatic artery.
Study NCT03224000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing Questionnaire
Description: Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT04465357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab-Aooe 140 MG/ML [Aimovig]
Description: 140 mg/mL administered subcutaneously
Study NCT03224000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing Questionnaire
Description: Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT03224000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT03224000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Questionnaire
Description: Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT03224000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Strobe Procedure
Description: Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT03224000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Strobe Procedure
Description: Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study NCT03224000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning
Description: IMRT planned with MRI guidance.
Study NCT03224000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning
Description: IMRT planned by standard-of-care.
Study NCT03224000 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
Study NCT03224000 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
Study NCT00821964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: Given topically
Study NCT00821964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Given IV
Study NCT00821964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00821964 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study NCT00821964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT00347139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 (25, 100 & 400 mcg/day)
Description: 25, 100 and 400mcg/dose
Study NCT00347139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50mcg
Description: Salmeterol 50mcg
Study NCT01242670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ross River Virus Vaccine
Description: Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
Study NCT01006876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Continuous oral Coumadin therapy through the catheter ablation procedure
Study NCT01487317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity \< 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity \< 10, the active treatment will be stopped
Study NCT01487317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped
Study NCT04342351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs
Study NCT04342351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perindopril
Description: Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur
Study NCT04342351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test
Description: All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
Study NCT04342351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test
Description: All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
Study NCT04342351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
Study NCT04342351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
Study NCT01006876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
Study NCT01006876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
Study NCT00863343 — intervention group
Intervention type: BIOLOGICAL
Intervention: Public Health Notification
Description: For any H5 positive results, notification of the result to the site's local public health authorities.
Study NCT02649439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC -V
Description: Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus
Study NCT02649439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
Study NCT03267134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Device implanted into the Schlemm's canal of the eye for the purpose of providing a natural outflow pathway for aqueous humor. The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
Study NCT03267134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic surgery
Description: Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
Study NCT00282113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ProBioPlus
Description: ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
Study NCT00282113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culturelle
Description: Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
Study NCT00282113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
Study NCT02276989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only.
Study NCT02276989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine
Description: On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week.
Study NCT02276989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
Study NCT01262157 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Vascuspec)
Description: Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
Study NCT01262157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity shock wave therapy
Description: Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
Study NCT02189343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215 in combination with pomalidomide and dexamethasone
Description: Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
Study NCT04281758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage
Description: 16 oz (473.2 ml)
Study NCT04281758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage
Description: 16 oz (473.2 ml)
Study NCT02084108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intervention
Description: intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
Study NCT01656135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood drawing for immune monitoring and questionnaires
Study NCT02027545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
Study NCT02027545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Education
Description: Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
Study NCT02027545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Education
Description: Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
Study NCT00208156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study NCT02770183 — intervention group
Intervention type: DEVICE
Intervention: Imacor
Description: In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive.
Study NCT00784212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Study NCT00784212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02827903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Rosuvastatin
Description: Group I: Metformin + Rosuvastatin,
Study NCT01328301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
Study NCT02027545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance Measure Modification
Description: The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
Study NCT02027545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Performance Measure Modification
Description: The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
Study NCT02027545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simple Informational Booklet
Description: A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
Study NCT01962766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myofunctionnal therapy
Study NCT01962766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instructions
Study NCT04075682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inserts with efficacy messages
Description: Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.
Study NCT04075682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on packs
Description: Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
Study NCT02827903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin + placebo
Description: Group II: Metformin + placebo,
Study NCT03910205 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay
Study NCT03217383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MATRx plus
Description: The MATRx plus test is a 2- or 3-night home sleep test that uses temporary titration trays to move the lower jaw in response to respiratory events. The purpose of the test is to predict oral appliance therapy outcome, and to provide a protrusive position for individuals predicted to experience therapeutic success.
Study NCT00331669 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: deep brain stimulation
Description: high frequency stimulation
Study NCT01118793 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: 150 mg dosage of Clopidogrel for 7 to 10 days.
Study NCT02827903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo + Rosuvastatin
Description: Group III: placebo + Rosuvastatin
Study NCT00937469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills training, parental tr. and standard tr.
Description: Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
Study NCT00937469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.